Skip to main content

Table 3 Change in loss of ambulation

From: The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review

Country/countries

Name of subgroup

First author & publication year

Sample size

Mean age

Loss of ambulation (%)

Time point for follow up

Loss of Ambulation (n)@FU

Loss of ambulation (%)@FU

Italy

Ambulatory <350 m(6MWT), <7y

Pane, 2014 [34]

9

5.8

0

3y

2

22.22

Ambulatory ≥350 m(6MWT), <7y

19

6.16

1

5.26

Ambulatory <350 m(6MWT), ≥7y

25

9.87

16

64.00

Ambulatory ≥350 m(6MWT), ≥7y

43

8.9

5

11.63

Ambulatory-boys

96

NR

1y

3

3.00

2y

16

17.00

3y

27

29.00

Italy; Belgium

Ambulatory ≥100 m

Pane, 2014 [42]

191

7.9

1y

4

2.10

NR

Boys

Mah, 2012 [44]

340

12.0

43

194

57.06

Sweden

All DMD

Soderpalm, 2012 [45]

24

NR

17

4y

9

38.00

UK

Boys

Ricotti, 2012 [47]

400

NR

7Y

NR

Median loss of ambulation was 14 years in Daily versus 12 years in Intermittent prednisolone